AstraZeneca (AZN)
Enhertu demonstrated a median PFS of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced NSCLC in DESTINY-Lung04
Enhertu demonstrated a median PFS of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced NSCLC in DESTINY-Lung04
📈 **POSITIVE** • High confidence analysis (95%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical